US Patent Issued to Rosemont Pharmaceuticals on Sept. 23 for "Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability" (British Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,857, issued on Sept. 23, was assigned to Rosemont Pharmaceuticals Ltd. (Leeds, Great Britain).

"Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability" was invented by Tajamal Mustafa (Leeds, Great Britain), Mark Kneale Foley (Leeds, Great Britain), Hayley Louise Lonergan (Leeds, Great Britain) and David Robert Thompson (Leeds, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application relates to pharmaceutical compositions comprising a pharmaceutically effective amount of topiramate particles dispersed in suspension, wherein the composition is suitable for oral delivery. The pre...